Vial Announces $67M Series B Led by General Catalyst
Read Vial's feature in the WSJ

Vial Introduces New Scientific Advisory Board Member, Roberta Brinton of The University of Arizona Health Sciences to Their Neurology CRO

roberta brinton
roberta brinton

San Francisco, CA. October 16, 2022 — Vial welcomes Dr. Roberta Brinton as a new Central Nervous System (CNS) advisory board member. Dr. Brinton is the Director of the Center for Innovation in Brain Science and founder of NeuTherapeutics, a biotechnology company developing regenerative therapeutics for neurodegenerative diseases including Alzheimer’s and precision strategies that preserve women’s brain health.

Dr. Brinton is an internationally recognized neuroscientist and a leading expert in the field of Alzheimer’s and regenerative therapeutics. She is paving the way for innovative therapeutic development in neurology and has received numerous awards and recognition for her research and STEM education initiatives.

Dr. Brinton has been named “Scientist of the Year” by Alzheimer’s Drug Discovery Foundation, “Woman of the Year” by the California State Senate, “Science Educator of the Year” by the Society for Neuroscience, Arizona Bioscientist of the Year, and U.S. News & World Report’s “Ten Best Minds.” In 2010, she received one of the nation’s highest civilian honors, the Presidential Citizens Medal, presented by President Barack Obama, for promoting careers in science, technology, engineering, and mathematics (STEM) among minority students.

“Vial is reimagining what the clinical trial space could look like through the lens of technology. In the neurology space, that is exactly the creative vision you need when developing new treatment methods,” said Dr. Brinton on joining Vial’s Scientific Advisory Board.

Vial is a tech-enabled CRO providing cutting-edge clinical trial management services that deliver faster, more efficient trials for biotech sponsors. The Vial Neurology CRO distinguishes itself by leveraging digital technology, such as its Vial Technology Platform that brings together eSourceEDCeTMF, and ePro, in one connected system to streamline site processes. These best-in-class CRO services will accelerate the development of new therapies and devices for neurology and CNS sponsors.

Dr. Brinton will act as a founding scientific advisor to Vial’s Neurology CRO to refine the CRO to support neurology sponsors’ and patients’ greatest needs.

“We are thrilled to have such a renowned neuroscientist as Dr. Brinton on our neurology and CNS advisory board. She will be integral to Vial running more efficient and effective neurology trials,” said Simon Burns, Co-Founder and CEO of Vial.

In addition to Vial’s Neurology CRO Advisory Board, Dr. Brinton currently serves on the NIH Director’s Center for Scientific Review Advisory Council and the Board of Governors of the Alzheimer’s Drug Discovery Foundation (New York). She also serves on the scientific review boards for the National Institute on Aging Review Panels, the Alzheimer’s Drug Discovery Foundation, and the Alzheimer’s Association. Dr. Brinton is also a member of the Society for Neuroscience and the International Brain Research Organization/World Federation of Neuroscientists.

About Vial: Vial is a tech-enabled, next-generation CRO that promises faster and higher-quality execution of trials. The Vial Contract Research Organization (CRO) delivers on the promise of faster trials through its innovative technology platform that powers trials end-to-end from site startup to database lock. The key to Vial’s tech-enabled platform is Vial’s modern, intuitive Electronic Source and powerful tooling for CRAs that enables considerable efficiencies. Vial operates across multiple Therapeutic Areas (Dermatology CROOphthalmology CROOncology CROGastroenterology CRO, and Neurology CRO). Vial is a San Francisco, California-based company with over 125 employees and has run over 750 trials from Phase I through Phase IV.

Contact Us

Note: If you are looking to participate in a clinical trial, please click here
Name(Required)
By submitting, you are agreeing to our terms and privacy policy
This field is for validation purposes and should be left unchanged.